GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyka Labs Ltd (BOM:500259) » Definitions » Cash Conversion Cycle

Lyka Labs (BOM:500259) Cash Conversion Cycle : 69.41 (As of Mar. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Lyka Labs Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Lyka Labs's Days Sales Outstanding for the three months ended in Mar. 2024 was 88.7.
Lyka Labs's Days Inventory for the three months ended in Mar. 2024 was 72.95.
Lyka Labs's Days Payable for the three months ended in Mar. 2024 was 92.24.
Therefore, Lyka Labs's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 69.41.


Lyka Labs Cash Conversion Cycle Historical Data

The historical data trend for Lyka Labs's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyka Labs Cash Conversion Cycle Chart

Lyka Labs Annual Data
Trend Jun14 Jun15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -160.27 -136.90 -53.53 35.87 57.05

Lyka Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.41 56.76 63.05 49.55 69.41

Competitive Comparison of Lyka Labs's Cash Conversion Cycle

For the Biotechnology subindustry, Lyka Labs's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyka Labs's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Lyka Labs's Cash Conversion Cycle falls into.



Lyka Labs Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Lyka Labs's Cash Conversion Cycle for the fiscal year that ended in Mar. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=77.33+67.24-87.52
=57.05

Lyka Labs's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=88.7+72.95-92.24
=69.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lyka Labs  (BOM:500259) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Lyka Labs Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Lyka Labs's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyka Labs (BOM:500259) Business Description

Traded in Other Exchanges
Address
30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment viz. pharmaceuticals. The Company has presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.

Lyka Labs (BOM:500259) Headlines

No Headlines